People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

A new study published in the Journal of Medical Internet Research has found that regular participation in dance classes can ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

A Colorado Springs family hopes to win what they believe would be a landmark legal verdict by proving to jurors next month ...

Onapgo is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with advanced disease.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

Feixiong Cheng, PhD, and a Cleveland Clinci research team have successfully applied advanced artificial intelligence genetics ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...